Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 3:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: drug holiday Clear all
Recruiting Not applicable Interventional

Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial

NCT07188532
View directory record Official record
Conditions
Ewing Sarcoma, Round Cell Sarcoma With EWSR1-non-ETS Fusion
Interventions
Biospecimen Collection, Chemotherapy, Computed Tomography, Conventional Radiotherapy, Definitive Surgical Resection, Dose-escalated Radiation Therapy, Electronic Health Record Review, External Beam Radiation Therapy, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
2 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Phoenix, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 17, 2026, 3:16 PM EDT
Completed Phase 1 Interventional

ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

NCT05085548
View directory record Official record
Conditions
Advanced Pancreatic Cancer, Solid Tumor Malignancies
Interventions
ProAgio Dose Levels (DL) 1,2,3, ProAgio Dose Levels (DL) 4,5,6, ProAgio Dose Levels 4a,5a,6a
Drug
Lead sponsor
ProDa BioTech, LLC
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 17, 2026, 3:16 PM EDT
Recruiting Phase 2 Interventional

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

NCT05534438
View directory record Official record
Conditions
Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer, Metastatic Breast Carcinoma, ER+ Breast Cancer, HER2+ Breast Cancer
Interventions
Stereotactic body radiotherapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 17, 2026, 3:16 PM EDT
Not listed Phase 4 Interventional

The Impact of Statin Holiday in Dialysis Patients Over 70 Years Old on Mental Function, Physical Function and Frailty

NCT03663049
View directory record Official record
Conditions
ESRD, Cardiovascular Diseases
Interventions
discontinue statin
Drug
Lead sponsor
Loyola University
Other
Eligibility
70 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 17, 2026, 3:16 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

NCT02010567
View directory record Official record
Conditions
Rectal Cancer
Interventions
CRLX101, Capecitabine, Radiotherapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
6
States / cities
Denver, Colorado • Indianapolis, Indiana • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 17, 2026, 3:16 PM EDT
Not listed Phase 4 Interventional

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

NCT04048577
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Dosing Interruption of Natalizumab
Drug
Lead sponsor
Berkovich, Regina MD, PhD Inc.
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 17, 2026, 3:16 PM EDT
Completed Phase 3 Interventional Results available

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

NCT02569242
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Nivolumab, Docetaxel/Paclitaxel
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
20 Years and older
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
Gilbert, Arizona • Washington D.C., District of Columbia • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Sep 17, 2026, 3:16 PM EDT
Completed Not applicable Interventional

Medication Adherence Telemonitoring to Reduce Heart Failure Readmissions

NCT02378571
View directory record Official record
Conditions
Heart Failure
Interventions
Medication adherence telemonitoring
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 17, 2026, 3:16 PM EDT
Terminated Phase 1 Interventional

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

NCT05083481
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ASP1570, pembrolizumab, Trifluridine + Tipiracil, Bevacizumab, Docetaxel, Oxaliplatin, Leucovorin, 5-Fluorouracil, Irinotecan, Pemetrexed, Carboplatin
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
12
States / cities
Fullerton, California • Los Angeles, California • Sarasota, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 17, 2026, 3:16 PM EDT
Terminated Phase 1 Interventional

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT02277184
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT)
Drug · Radiation
Lead sponsor
Julie E. Bauman, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 17, 2026, 3:16 PM EDT
Completed Phase 1 Interventional

Redirected High Affinity Gag-Specific Autologous T Cells for HIV Gene Therapy

NCT00991224
View directory record Official record
Conditions
HIV Infections
Interventions
WT-gag-TCR modified T cells, α/6-gag-TCR modified T cells, STI or Drug Holiday
Biological · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Sep 17, 2026, 3:16 PM EDT
Completed Phase 3 Interventional Results available

Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth

NCT01109849
View directory record Official record
Conditions
ADHD, Growth
Interventions
behavior therapy, Extended release (ER) methylphenidate product, monitoring, drug holiday, caloric supplement
Behavioral · Drug · Other + 1 more
Lead sponsor
Florida International University
Other
Eligibility
5 Years to 12 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Sep 17, 2026, 3:16 PM EDT
Terminated Not applicable Interventional Results available

Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma

NCT02039778
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma, Brain Tumors, Anaplastic Astrocytoma
Interventions
Stem Cell Radiotherapy (ScRT) and Temozolomide
Radiation
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 17, 2026, 3:16 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein

NCT01887717
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TheraSphere®, Sorafenib
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 17, 2026, 3:16 PM EDT
Terminated Phase 2 Interventional Results available

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

NCT04364048
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Carcinoma
Interventions
Induction Durvalumab, Chemotherapy, Radiation, Consolidation durvalumab
Drug · Radiation
Lead sponsor
Rachel Sanborn
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Wichita, Kansas • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Sep 17, 2026, 3:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study of Virtually Supervised Mouth Rinses and Flossing

NCT05600231
View directory record Official record
Conditions
Healthy
Interventions
LISTERINE COOL MINT Antiseptic Mouthwash, LISTERINE COOL MINT ZERO Alcohol Mouthwash, Reach Unflavored Waxed Dental Floss, Colgate Cavity Protection Toothpaste
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 17, 2026, 3:16 PM EDT
Recruiting Phase 1 Interventional

Chronic CED of TPT for Recurrent Malignant Glioma

NCT06666712
View directory record Official record
Conditions
Brain Tumor, Recurrent, Malignant Glioma (WHO Grade III or IV), IDH1/IDH2 Mutation
Interventions
Topotecan
Drug
Lead sponsor
Jeffrey N. Bruce
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 17, 2026, 3:16 PM EDT
Completed Phase 1Phase 2 Interventional

A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma

NCT00304525
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
RAF265
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
10
States / cities
Aurora, Colorado • Augusta, Georgia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 17, 2026, 3:16 PM EDT
Not listed Not applicable Interventional

Changes in Biochemical Markers of Bone Turnover (Serum CTX and PlNP) After Initiation of a "Drug Holiday" From Bisphosphonates

NCT02575157
View directory record Official record
Conditions
Osteoporosis
Interventions
No intervention
Other
Lead sponsor
National Bone Health Alliance
Other
Eligibility
50 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Sep 17, 2026, 3:16 PM EDT
Completed Not applicable Interventional Results available

Targeting Obesity to Optimize Health in Cardiac Rehab (TOPCARE)

NCT03423238
View directory record Official record
Conditions
Obesity, Weight Loss, CHD - Coronary Heart Disease
Interventions
Exercise, Health Education, Exercise Compliance, Calorie-Restricted Diet, Behavioral Modification, Weight-Loss Compliance, Dietary Counseling
Other · Behavioral · Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 17, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

NCT03715829
View directory record Official record
Conditions
Active Non-segmental Vitiligo
Interventions
PF-06651600, placebo, PF06700841, narrow-band UVB phototherapy
Drug · Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
40
States / cities
Huntington Beach, California • Irvine, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 17, 2026, 3:16 PM EDT
Recruiting Phase 2 Interventional

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

NCT05305924
View directory record Official record
Conditions
ER-Positive Breast Cancer, HER2-negative Breast Cancer
Interventions
Fulvestrant Run-In
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 17, 2026, 3:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study of Virtually Supervised Mouthwash and Interdental Brushes

NCT05756673
View directory record Official record
Conditions
Healthy
Interventions
Colgate Cavity Protection Toothpaste, LISTERINE ZERO Alcohol Mouthwash COOL MINT, LISTERINE COOL MINT Antiseptic Mouthwash, TePe Original Interdental Brush
Drug · Device
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Sep 17, 2026, 3:16 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors

NCT00839631
View directory record Official record
Conditions
Solid Tumors
Interventions
EC D-3263 HCl
Drug
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Sep 17, 2026, 3:16 PM EDT